{
    "organizations": [],
    "uuid": "c7c5987353837c21126aa2c3323f6fb61a8e87c4",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/05/04/globe-newswire-zogenix-to-release-first-quarter-2018-financial-results-and-host-conference-call-and-webcast-on-may-9.html",
    "ord_in_thread": 0,
    "title": "Zogenix to Release First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 9",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "EMERYVILLE, Calif., May 04, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31, 2018, after the market close, and will host a corporate update conference call and webcast on Wednesday, May 9, 2018, at 4:30 PM Eastern Time.\nConference Call Details\nWednesday, May 9 th @ 4:30pm Eastern Time/1:30pm Pacific Time\nToll Free: 866-548-4713 International: 323-794-2093 Conference ID: 7186111 Webcast: http://public.viavid.com/index.php?id=129538 Replays, available through May 23 rd\nDomestic: 844-512-2921 International: 412-317-6671 Replay PIN: 7186111\nAbout Zogenix\nZogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.\nFor more information, visit www.zogenix.com .\nCONTACT:\nInvestors:\nAndrew McDonald\nFounding Partner, LifeSci Advisors LLC\n646-597-6987\nAndrew@LifeSciAdvisors.com\nSource:Zogenix, Inc.",
    "published": "2018-05-04T16:00:00.000+03:00",
    "crawled": "2018-05-04T18:52:06.026+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "emeryville",
        "may",
        "globe",
        "newswire",
        "zogenix",
        "nasdaq",
        "zgnx",
        "pharmaceutical",
        "company",
        "developing",
        "therapy",
        "treatment",
        "rare",
        "central",
        "nervous",
        "system",
        "cns",
        "disorder",
        "today",
        "announced",
        "report",
        "financial",
        "result",
        "first",
        "quarter",
        "ended",
        "march",
        "market",
        "close",
        "host",
        "corporate",
        "update",
        "conference",
        "call",
        "webcast",
        "wednesday",
        "may",
        "pm",
        "eastern",
        "time",
        "conference",
        "call",
        "detail",
        "wednesday",
        "may",
        "th",
        "eastern",
        "pacific",
        "time",
        "toll",
        "free",
        "international",
        "conference",
        "id",
        "webcast",
        "http",
        "replay",
        "available",
        "may",
        "rd",
        "domestic",
        "international",
        "replay",
        "pin",
        "zogenix",
        "zogenix",
        "nasdaq",
        "zgnx",
        "pharmaceutical",
        "company",
        "committed",
        "developing",
        "commercializing",
        "cns",
        "therapy",
        "address",
        "specific",
        "clinical",
        "need",
        "people",
        "living",
        "orphan",
        "cns",
        "disorder",
        "need",
        "innovative",
        "treatment",
        "alternative",
        "improve",
        "daily",
        "functioning",
        "information",
        "visit",
        "contact",
        "investor",
        "andrew",
        "mcdonald",
        "founding",
        "partner",
        "lifesci",
        "advisor",
        "llc",
        "andrew",
        "source",
        "zogenix",
        "inc"
    ]
}